読み込み中
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
前日終値
$11.77
+$0.30 · +2.62%
日中の時刻はETです。市場データは遅延する場合があります。
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
日中レンジ
現在 $11.77
52週レンジ
現在 $11.77
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
73
割安
センチメント
60
まちまち
リスク
38
中程度のリスク
モメンタム
53
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
日中レンジ
現在 $11.77
52週レンジ
現在 $11.77
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$19.50
上昇余地（65.68%）この株式へのエクスポージャーを報告している上場投資信託です。
ARK Israel Innovative Technology ETFIZRL168.44万1.29%1.37億 USD0.49%$28.36+1.61%
Amplify BlueStar Israel Technology ETFITEQ85.2万0.79%1.08億 USD0.75%$62.0587+1.33%
ActivePassive International Equity ETFAPIE20.65万0.02%11.41億 USD0.45%$38.56+0.65%
Even Herd Long Short ETFEHLS17.19万0.30%5883.5万 USD2.62%$25.4482+0.28%
iShares Neuroscience and Healthcare ETFIBRN4.1万0.65%635.78万 USD0.47%$31.81+1.33%
Defiance Autism Impact ETFASD2.98万2.25%132.35万 USD0.79%$26.615+0.62%ARK Israel Innovative Technology ETFIZRLAmplify BlueStar Israel Technology ETFITEQActivePassive International Equity ETFAPIEEven Herd Long Short ETFEHLSiShares Neuroscience and Healthcare ETFIBRNDefiance Autism Impact ETFASDAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
